文献速递生殖医学

胚胎移植前后使用缩宫素受体拮抗剂与IVF治疗结局的系统综述与Meta分析

Is oxytocin receptor antagonist administration around embryo transfer associated with IVF treatment success? A systematic review and meta-analysis.
PubMed 文献 · Reprod Biomed Online · 2021-08-28

该系统综述与Meta分析纳入11项RCT,评估胚胎移植前后使用缩宫素受体拮抗剂(OTR-a)对IVF结局的影响。结果显示,OTR-a组临床妊娠率显著升高(RR 1.31,95%CI 1.13-1.51,P=0.0002),但活产率无统计学显著差异(RR 1.09,95%CI 0.98-1.20,P=0.11)。低偏倚风险研究的敏感性分析同样提示临床妊娠率升高(RR 1.11,95%CI 1.01-1.22,P=0.03)。

要点

  • 胚胎移植前后使用OTR-a可显著提高临床妊娠率,但活产率改善未达统计学显著。
  • 低偏倚风险研究的敏感性分析仍显示临床妊娠率升高,但效应量较小。
  • 现有证据尚不足以充分证实OTR-a改善IVF疗效,需更多高质量研究验证。

核心结论

  • 在IVF治疗中,胚胎移植前后使用OTR-a可能提高临床妊娠率,但对活产率的影响未达统计学显著,现有治疗效应较小且证据尚不充分。

研究设计与样本

  • 系统文献综述与Meta分析,检索多个数据库,纳入比较胚胎移植前、中、后使用OTR-a与安慰剂/无治疗的RCT,共识别11项符合条件RCT。

主要发现

  • 临床妊娠率在OTR-a组显著更高(RR 1.31,95%CI 1.13-1.51,P=0.0002,I2=61%,11项研究,n=3611)。
  • 活产率在OTR-a组无统计学显著差异(RR 1.09,95%CI 0.98-1.20,P=0.11,I2=25%,5项研究,n=2765)。
  • 低偏倚风险研究的敏感性分析显示临床妊娠率更高(RR 1.11,95%CI 1.01-1.22,P=0.03,I2=5%,5项RCT,n=2765)。

关键数值与推荐

  • 纳入的RCT中,活性药物为静脉阿托西班(n=7)、皮下巴鲁西班(n=1)和口服诺拉西班(n=3)。

临床怎么用

  • OTR-a在胚胎移植前后的应用可能作为提高IVF临床妊娠率的潜在辅助措施,但鉴于活产率获益不显著且证据不充分,临床决策需个体化并充分告知患者。

局限性

  • 观察到的治疗效应较小,且未得到充分证实;部分分析存在异质性(如临床妊娠率I2=61%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A systematic literature review and meta-analysis was conducted to evaluate whether the administration of an oxytocin receptor antagonist (OTR-a) around embryo transfer is associated with live birth and pregnancy achievement in IVF treatment. Multiple databases were searched for randomized controlled trials (RCT) comparing the outcome of IVF treatment with administration of an OTR-a before, during or after embryo transfer versus administration of placebo/nil. The literature search identified 11 eligible RCT. The active compound was intravenous atosiban (n = 7), subcutaneous barusiban (n = 1) and oral nolasiban (n = 3). Clinical pregnancy rate was significantly higher in women receiving an OTR-a around embryo transfer (relative risk [RR] 1.31, 95% confidence interval [CI] 1.13-1.51, P = 0.0002, I2 = 61%, n = 11 studies, n = 3611); however, live birth rate was not statistically significantly affected (RR 1.09, 95% CI 0.98-1.20, P = 0.11, I2 = 25%, n = 5 studies, n = 2765). A sensitivity analysis on low risk of bias studies likewise indicates a higher clinical pregnancy chance (RR 1.11, 95% CI 1.01-1.22, P = 0.03, I2 = 5%, n = 5 RCT, n = 2765). OTR-a administration in IVF treatment has the potential to increase IVF efficacy, although the treatment effects observed so far are small and have not been sufficiently corroborated.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Neumann K, Griesinger G. Is oxytocin receptor antagonist administration around embryo transfer associated with IVF treatment success? A systematic review and meta-analysis. Reprod Biomed Online. 2021. PMID: 34686417. doi:10.1016/j.rbmo.2021.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。